Study of Karenitecin (BNP1350) in Patients With Brain Tumors

* Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma. * Evidence of measurable recurrent or residual primary CNS neoplasm. * An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy. * Hematocrit \> 29%, ANC \> 1,500, platelets \> 125,000 * Serum creatinine \< 1.5 mg/dl, BUN \< 25 mg/dl, serum SGOT and bilirubin \< 1.5 times upper limit of normal * Negative pregnancy test for female patients